Price Action to Note: Egalet Corp Can’t Burn Your Long Portfolio. Has Another Strong Session

Price Action to Note: Egalet Corp Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of Egalet Corp (NASDAQ:EGLT) is a huge mover today! About 991,642 shares traded hands or 197.59% up from the average. Egalet Corp (NASDAQ:EGLT) has risen 6.80% since March 4, 2016 and is uptrending. It has underperformed by 1.24% the S&P500.
The move comes after 6 months positive chart setup for the $176.94 million company. It was reported on Oct, 7 by Barchart.com. We have $18.08 PT which if reached, will make NASDAQ:EGLT worth $253.02M more.

Analysts await Egalet Corp (NASDAQ:EGLT) to report earnings on November, 2. They expect $-0.87 earnings per share, down 7.41% or $0.06 from last year’s $-0.81 per share. After $-0.97 actual earnings per share reported by Egalet Corp for the previous quarter, Wall Street now forecasts -10.31% EPS growth.

According to Zacks Investment Research, “Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.”

Insitutional Activity: The institutional sentiment decreased to 1.79 in 2016 Q2. Its down 0.13, from 1.92 in 2016Q1. The ratio is negative, as 9 funds sold all Egalet Corp shares owned while 10 reduced positions. 16 funds bought stakes while 18 increased positions. They now own 13.97 million shares or 0.03% less from 13.98 million shares in 2016Q1.
Jpmorgan Chase accumulated 0% or 342 shares. Rhumbline Advisers accumulated 25,267 shares or 0% of the stock. Tiverton Asset Mngmt Limited Liability Corp has invested 0.38% of its portfolio in Egalet Corp (NASDAQ:EGLT). Summit Securities Group Limited Liability holds 0.03% of its portfolio in Egalet Corp (NASDAQ:EGLT) for 10,636 shares. Barclays Public Ltd Liability holds 13,272 shares or 0% of its portfolio. The New Jersey-based Jacobs Levy Equity Management has invested 0.01% in Egalet Corp (NASDAQ:EGLT). Franklin last reported 0.01% of its portfolio in the stock. Deutsche Financial Bank Ag has 0% invested in the company for 5,594 shares. Rock Springs Capital Mgmt Lp holds 0.11% of its portfolio in Egalet Corp (NASDAQ:EGLT) for 300,000 shares. National Bank Of New York Mellon, a New York-based fund reported 54,334 shares. Fmr Limited Com accumulated 3.76 million shares or 0% of the stock. New Jersey Better Educational Savings Tru holds 74,000 shares or 0.25% of its portfolio. Broadfin Capital Llc owns 1.13M shares or 0.55% of their US portfolio. Blackrock Institutional Tru Com Na has 240,175 shares for 0% of their US portfolio. Eagle Advisors Limited Liability Corp has invested 0% of its portfolio in Egalet Corp (NASDAQ:EGLT).

More news for Egalet Corp (NASDAQ:EGLT) were recently published by: Marketwatch.com, which released: “Egalet Corp. NASDAQ: EGLT” on February 11, 2014. Prnewswire.com‘s article titled: “Egalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 …” and published on June 28, 2016 is yet another important article.

EGLT Company Profile

Egalet Corporation, incorporated on August 21, 2013, is a specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Firm is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s Guardian Technology is a polymer matrix tablet technology that utilizes a manufacturing process, injection molding, which results in tablets with controlled-release properties, as well as physical and chemical features that have been demonstrated to resist both common and rigorous methods of manipulation. The Company’s Guardian Technology can be used to create tablets. The Company’s Guardian Technology platform, which combines abuse-deterrent features and precision delivery, is applied across various classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients (APIs) with similar or different release profiles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment